> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# EUA for Lucira Covid-19 and Flu Test
- URL: https://www.fdaweb.com/eua-for-lucira-covid-19-and-flu-test/
- Published: 2022-11-23T12:00:00.000Z
- Updated: 2026-09-14T18:07:27.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5153255

FDA issued 11/22 an emergency use authorization for the Lucira Covid-19 and Flu Test for use in a point-of-care setting. An agency [notice](https://www.fda.gov/news-events/press-announcements/fda-roundup-november-22-2022?ref=fdaweb.com) says the Lucira product is a single-use molecular test intended for the detection of both the SARS-CoV-2 virus and influenza A or B if a patient is suspected of respiratory viral infection consistent with Covid-19.

The test can be used in persons age 2 or older and is collected by nasal swab by a healthcare provider in a point-of-care setting, the notice says. FDA says negative test results should be confirmed with another FDA-authorized molecular test.